• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in cardiovascular disease. >Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy
【24h】

Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy

机译：沙比特比/缬沙坦治疗心血管疾病的证据：迄今为止的证据和治疗方法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world. Mortality from CV disease had plateaued in the recent years raising concerning alarms about the sustained efficacy of available preventive and treatment options. Heart failure (HF) is among the major contributors to the CV-related health care burden, a persisting concern despite the use of clinically proven guideline-directed therapies. A requirement for more efficient medical therapies coupled with recent advances in bio-innovation led to the creation of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), which demonstrated substantial CV benefit when compared with the standard of care, enalapril, in patients with HF and reduced ejection fraction. Further investigations of this novel combination ARNI at the tissue level shed light into the anti-remodeling and cardioprotective effects of sacubitril/valsartan, while clinical studies in the phenotypes of HF with preserved ejection fraction, hypertension and subsets, coronary outcomes, postmyocardial infarction, and renal disease suggested that this combination could be beneficial across a wide spectrum of CV disease. Sacubitril/valsartan is a much-needed therapeutic advance in the avenue of CV disease.
机译：在发展中国家和发达国家，心血管疾病是发病率和死亡率的主要原因。近年来，来自心血管疾病的死亡率已趋于平稳，引发了有关可用预防和治疗方案持续效力的警报。心力衰竭（HF）是与CV相关的医疗保健负担的主要贡献者，尽管使用了临床证明的指南指导疗法，但这一问题仍然令人担忧。对更有效药物治疗的需求以及生物创新的最新进展，导致了sacubitril / valsartan，一种血管紧张素受体-neprilysin抑制剂（ARNI）的产生，与依那普利标准治疗相比，它具有显着的心血管益处。 HF和射血分数降低的患者。在组织水平上对该新型组合ARNI的进一步研究揭示了沙比特利/缬沙坦的抗重塑和心脏保护作用，同时针对射血分数，高血压和亚群，冠状动脉预后，心肌梗死和肾脏疾病表明，这种组合可能对广泛的心血管疾病有益。沙必比/缬沙坦是CV疾病领域急需的治疗进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号